EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCL

Brach, D; Johnston-Blackwell, D; Drew, A; Lingaraj, T; Motwani, V; Warholic, NM; Feldman, I; Plescia, C; Smith, JJ; Copeland, RA; Keilhack, H; Chan-Penebre, E; Knutson, SK; Ribich, SA; Raimondi, A; Thomenius, MJ

Raimondi, A; Thomenius, MJ (reprint author), Epizyme Inc, 400 Technol Sq,4th Floor, Cambridge, MA 02139 USA.

MOLECULAR CANCER THERAPEUTICS, 2017; 16 (11): 2586

Abstract

The EZH2 small-molecule inhibitor tazemetostat (EPZ-6438) is currently being evaluated in phase II clinical trials for the treatment of non-Hodgkin ly......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索